These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36851143)

  • 1. Risk Analysis Stratification of CIN 2+ Development in a Cohort of Women Living with HIV with Negative Pap Smear and HR-HPV Test during a Long-Term Follow-Up.
    Gardella B; Agarossi A; Dominoni M; Pagano I; Del Frati S; Di Giminiani M; Cammarata S; Melito C; Pasquali MF; Zanchi L; Savasi V; Spinillo A
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study.
    Branca M; Costa S; Mariani L; Sesti F; Agarossi A; di Carlo A; Galati M; Benedetto A; Ciotti M; Giorgi C; Criscuolo A; Valieri M; Favalli C; Paba P; Santini D; Piccione E; Alderisio M; De Nuzzo M; di Bonito L; Syrjänen K
    Eur J Gynaecol Oncol; 2004; 25(6):689-98. PubMed ID: 15597844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of high-grade cervical abnormality risks in women living with and without human immunodeficiency virus undergoing routine cervical-cancer screening.
    Castle PE; Befano B; Schiffman M; Wentzensen N; Lorey T; Poitras N; Hyer M; Cheung LC
    Prev Med; 2022 Sep; 162():107157. PubMed ID: 35810936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of visual inspection with acetic acid, Pap smear, or high-risk human papillomavirus testing in women living with HIV/AIDS for posttreatment cervical cancer screening: same tests, different priorities.
    Omenge Orang'o E; Liu T; Christoffersen-Deb A; Itsura P; Oguda J; Washington S; Chumba D; Pisharodi L; Cu-Uvin S; Rositch AF
    AIDS; 2017 Jan; 31(2):233-240. PubMed ID: 28002084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term observational approach in women with histological diagnosis of cervical low-grade squamous intraepithelial lesion: an Italian multicentric retrospective cohort study.
    Ciavattini A; Serri M; Di Giuseppe J; Liverani CA; Gardella B; Papiccio M; Delli Carpini G; Morini S; Clemente N; Sopracordevole F
    BMJ Open; 2019 Jul; 9(7):e024920. PubMed ID: 31272971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results.
    Harris TG; Burk RD; Palefsky JM; Massad LS; Bang JY; Anastos K; Minkoff H; Hall CB; Bacon MC; Levine AM; Watts DH; Silverberg MJ; Xue X; Melnick SL; Strickler HD
    JAMA; 2005 Mar; 293(12):1471-6. PubMed ID: 15784870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Pap smear and human papilloma virus testing in the follow-up of women with cervical intraepithelial neoplasia grade 1 managed conservatively.
    Santos AL; Derchain SF; Sarian LO; Martins MR; Morais SS; Syrjänen KJ
    Acta Obstet Gynecol Scand; 2006; 85(4):444-50. PubMed ID: 16612707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.
    Keller MJ; Burk RD; Massad LS; Eltoum IE; Hessol NA; Castle PE; Anastos K; Xie X; Minkoff H; Xue X; D'Souza G; Flowers L; Levine AM; Colie C; Rahangdale L; Fischl MA; Palefsky JM; Strickler HD
    Clin Infect Dis; 2015 Nov; 61(10):1573-81. PubMed ID: 26187020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yield and mode of diagnosis of cervical intraepithelial neoplasia 3 or cancer among women with negative cervical cytology and positive high-risk human papillomavirus test results.
    Pretorius RG; Belinson JL; Peterson P; Azizi F; Lo A
    J Low Genit Tract Dis; 2013 Oct; 17(4):430-9. PubMed ID: 23595040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
    Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
    Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
    Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
    Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hr-HPV testing in the follow-up of women with cytological abnormalities and negative colposcopy.
    Carozzi F; Visioli CB; Confortini M; Iossa A; Mantellini P; Burroni E; Zappa M
    Br J Cancer; 2013 Oct; 109(7):1766-74. PubMed ID: 24008667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women.
    Konopnicki D; Manigart Y; Gilles C; Barlow P; de Marchin J; Feoli F; Larsimont D; Delforge M; De Wit S; Clumeck N
    J Infect Dis; 2013 Jun; 207(11):1723-9. PubMed ID: 23463709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Wait-and-see policy versus loop excision after two consecutive Pap-2 cervical smears: over time less surgery and an equivalent outcome; no substantial contribution to be expected from the detection of high risk human papillomavirus].
    Bekkers RL; Hanselaar AG; Melchers WJ; van Schaik JH; Boonstra H; Massuger LF
    Ned Tijdschr Geneeskd; 2003 Feb; 147(7):302-6. PubMed ID: 12622008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Human Papillomavirus (HPV) Genotypes in Cervicovaginal Secretions of Human Immunodeficiency Virus (HIV) Positive Indian Women and Correlation With Clinico-Virological Parameters.
    Lall M; Dar L; Bhatla N; Kumar P; Choudhary A; Mathur SR; Gupta RM
    Front Reprod Health; 2021; 3():695254. PubMed ID: 36303978
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential impact of combined high- and low-risk human papillomavirus infection on the progression of cervical intraepithelial neoplasia 2.
    Okadome M; Saito T; Tanaka H; Nogawa T; Furuta R; Watanabe K; Kita T; Yamamoto K; Mikami M; Takizawa K;
    J Obstet Gynaecol Res; 2014 Feb; 40(2):561-9. PubMed ID: 24147758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic excision of the cervix in women over 40 years with human papilloma virus persistency and normal cytology.
    Aarnio R; Wikström I; Gustavsson I; Gyllensten U; Olovsson M
    Eur J Obstet Gynecol Reprod Biol X; 2019 Jul; 3():100042. PubMed ID: 31404426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.